HARMONY BIOSCIENCES HOLDINGS, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$314.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$314.00K.
- HARMONY BIOSCIENCES HOLDINGS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$759.00K, a 524.02% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$11.00K.
- HARMONY BIOSCIENCES HOLDINGS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $118.00K, a 83.90% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $280.00K, a 337.50% increase from fiscal 2024.
- HARMONY BIOSCIENCES HOLDINGS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $64.00K, a 58.17% decline from fiscal 2023.
- HARMONY BIOSCIENCES HOLDINGS, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $153.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$314.00K 10-Q · filed 2026-08-04 | -$1.07M 10-Q · filed 2026-08-04 | -$1.08M derived: sum of 3 quarters · filed 2026-08-04 | -$966.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$759.00K 10-Q · filed 2026-05-07 | -$770.00K derived: sum of 2 quarters · filed 2026-05-07 | -$652.00K derived: sum of 3 quarters · filed 2026-05-07 | -$658.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $107.00K derived: sum of 2 quarters · filed 2026-02-24 | $101.00K derived: sum of 3 quarters · filed 2026-08-04 | $280.00K 10-K · filed 2026-02-24 |
| 2025-09-30 | $118.00K 10-Q · filed 2025-11-04 | $112.00K derived: sum of 2 quarters · filed 2026-08-04 | $291.00K 10-Q · filed 2025-11-04 | -$142.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$6.00K 10-Q · filed 2026-08-04 | $173.00K 10-Q · filed 2026-08-04 | -$260.00K derived: sum of 3 quarters · filed 2026-08-04 | $473.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $179.00K 10-Q · filed 2026-05-07 | -$254.00K derived: sum of 2 quarters · filed 2026-05-07 | $479.00K derived: sum of 3 quarters · filed 2026-05-07 | $416.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $300.00K derived: sum of 2 quarters · filed 2026-02-24 | $237.00K derived: sum of 3 quarters · filed 2026-02-24 | $64.00K 10-K · filed 2026-02-24 |
| 2024-09-30 | $733.00K 10-Q · filed 2025-11-04 | $670.00K derived: sum of 2 quarters · filed 2025-11-04 | $497.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$63.00K 10-Q · filed 2025-08-05 | -$236.00K 10-Q · filed 2025-08-05 | ||
| 2023-12-31 | $153.00K 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |